Clinical Trials
Overview
4 clinical trials. 146 treated breast cancer patients.
Substantial reduction in cancer recurrences over 5 years of follow-up. No reported serious adverse events. Well tolerated safety profile.
Thus far, the safety and efficacy of the GP2 immunotherapy have been tested in four clinical trials, where 146 patients have received treatment to date. The past trials consist of three Phase I clinical trials and one Phase IIb clinical trial.
Flamingo-01 Phase III Clinical Trial
The current, ongoing trial is a Phase III clinical trial registered with the name, Flamingo-01, and the identifier, NCT05232916. Greenwich LifeSciences is selecting and activating clinical sites from university-based hospitals and cooperative networks in the U.S. and Europe, and patients are being recruited and screened.
Flamingo-01 Phase III Clinical Trial
The current trial is a Phase III clinical trial registered with the name, Flamingo-01, and the identifier, NCT05232916. The cGMP manufacturing of GP2 for the trial is complete, Greenwich LifeSciences is selecting and activating clinical sites from university-based hospitals and cooperative networks in the U.S. and Europe, and patients are being recruited and screened.